Daily Archives: March 1, 2017

March 1, 2017 by Marilynn Marchione This 2009 colorized microscope image made available by the Sickle Cell Foundation of Georgia via the Centers for Disease Control and Prevention shows a sickle cell, left, and normal red blood cells of a patient with sickle cell anemia. Researchers say a French teen who was given gene therapy for sickle cell disease more than two years ago now has enough properly working red blood cells to dodge the effects of the disorder. The case is detailed in the March 2, 2017 issue of the New England Journal of Medicine. (Janice Haney Carr/CDC/Sickle Cell Foundation of Georgia via AP)

A French teen who was given gene therapy for sickle cell disease more than two years ago now has enough properly working red blood cells to dodge the effects of the disorder, researchers report.

The first-in-the-world case is detailed in Thursday's New England Journal of Medicine.

About 90,000 people in the U.S., mostly blacks, have sickle cell, the first disease for which a molecular cause was found. Worldwide, about 275,000 babies are born with it each year.

"Vexing questions of race and stigma have shadowed the history of its medical treatment," including a time when blacks who carry the bad gene were urged not to have children, spurring accusations of genocide, Keith Wailoo of Princeton University wrote in a separate article in the journal.

The disease is caused by a single typo in the DNA alphabet of the gene for hemoglobin, the stuff in red blood cells that carries oxygen. When it's defective, the cells sickle into a crescent shape, clogging tiny blood vessels and causing bouts of extreme pain and sometimes more serious problems such as strokes and organ damage. It keeps many people from playing sports and enjoying other activities of normal life.

A stem cell transplant from a blood-matched sibling is a potential cure, but in the U.S., fewer than one in five people have a donor like that. Pain crises are treated with blood transfusions and drugs, but they're a temporary fix. Gene therapy offers hope of a lasting one.

The boy, now 15, was treated at Necker Children's Hospital in Paris in October 2014. Researchers gave him a gene, taken up by his blood stem cells, to help prevent the sickling. Now, about half of his red blood cells have normal hemoglobin; he has not needed a transfusion since three months after his treatment and is off all medicines.

"It's not a cure but it doesn't matter," because the disease is effectively dodged, said Philippe Leboulch, who helped invent the therapy and helped found Bluebird Bio in Cambridge, Massachusetts, the company that treated the boy. The work was supported by a grant from the French government's research agency.

Bluebird has treated at least six others in the U.S. and France. Full results have not been reported, but the gene therapy has not taken hold as well in some of them as it did in the French teen. Researchers think they know why and are adjusting methods to try to do better.

Two other gene therapy studies for sickle cell are underway in the U.S.at the University of California, Los Angeles and Cincinnati Children's Hospitaland another is about to start at Harvard and Boston Children's Hospital using a little different approach.

"This work gives considerable promise" for a solution to a very common problem, said Dr. Stuart Orkin, a Boston Children's Hospital doctor who is an inventor on a patent related to gene editing.

"The results are quite good in this patient," he said of the French teen. "It shows gene therapy is on the right track."

Explore further: BCL11A-based gene therapy for sickle cell disease passes key preclinical test

More information: Gene therapy: ghr.nlm.nih.gov/primer/therapy/availability

2017 The Associated Press. All rights reserved.

A precision-engineered gene therapy virus, inserted into blood stem cells that are then transplanted, markedly reduced sickle-induced red-cell damage in mice with sickle cell disease, researchers from Dana-Farber/Boston Children's ...

Sickle cell disease and the blood disorder beta thalassemia affect more than 180,000 Americans and millions more worldwide. Both diseases can be made milder or even cured by increasing fetal hemoglobin (HbF) levels, but current ...

Scientists at the Center for Regenerative Medicine (CReM) at Boston Medical Center (BMC) and Boston University School of Medicine (BUSM) are creating an induced pluripotent stem cell (iPSC)-based research library that opens ...

UCLA stem cell researchers have shown that a novel stem cell gene therapy method could lead to a one-time, lasting treatment for sickle cell diseasethe nation's most common inherited blood disorder.

A team of researchers at the Stanford University School of Medicine has used a gene-editing tool known as CRISPR to repair the gene that causes sickle cell disease in human stem cells, which they say is a key step toward ...

Scientists have developed a new approach to repair a defective gene in blood-forming stem cells from patients with a rare genetic immunodeficiency disorder called X-linked chronic granulomatous disease (X-CGD). After transplant ...

A French teen who was given gene therapy for sickle cell disease more than two years ago now has enough properly working red blood cells to dodge the effects of the disorder, researchers report.

A research team, led by the University of Minnesota, has discovered a groundbreaking process to successfully rewarm large-scale animal heart valves and blood vessels preserved at very low temperatures. The discovery is a ...

Working with yeast and human cells, researchers at Johns Hopkins say they have discovered an unexpected route for cells to eliminate protein clumps that may sometimes be the molecular equivalent of throwing too much or the ...

By changing one small portion of a stimulus that influences part of one molecule's function, engineers and researchers at Washington University in St. Louis have opened the door for more insight into how the molecule is associated ...

A minimally invasive, fiber-optic technique that accurately measures the passive stretch and twitch contraction of living muscle tissue could someday be an alternative to the painful muscle biopsies used to diagnose and treat ...

An in-depth computational analysis of genetic variants implicated in both schizophrenia and rheumatoid arthritis by researchers at the University of Pittsburgh points to eight genes that may explain why susceptibility to ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Originally posted here:
Gene therapy lets a French teen dodge sickle cell disease - Medical Xpress

In 2017, Sangamo is conducting a Phase 1/2 clinical trial evaluating SB-913 as an in vivo genome editing treatment for MPS II. Sangamo is also conducting Phase 1/2 studies this year evaluating in vivo genome editing treatments SB-318 for MPS I, another rare lysosomal storage disorder, and SB-FIX for hemophilia B, a rare blood disease. Data from these studies and from a clinical trial for a fourth lead program, SB-525, a gene therapy approach for hemophilia A, are expected in late 2017 or early 2018.

Sangamo's In Vivo Genome Editing Approach Sangamo's ZFN-mediated in vivo genome editing approach makes use of the endogenous albumin gene locus, a highly expressing and liver-specific site that can be edited with ZFNs to accept and express therapeutic genes. The approach is designed to enable the patient's liver to permanently produce circulating therapeutic levels of a corrective protein. The ability to permanently integrate the therapeutic gene in a highly specific, targeted fashion significantly differentiates Sangamo's in vivo genome editing approach from conventional AAV cDNA gene therapy. Ultimately, the target population for these programs will include pediatric patients, and it will be important in this population to be able to produce stable levels of therapeutic protein for the lifetime of the patient.

About Sangamo Therapeutics Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is advancing Phase 1/2 clinical programs in hemophilia A and hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has a strategic collaboration with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences. For more information about Sangamo, visit the Company's website at http://www.sangamo.com.

Forward Looking Statements This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation references relating to research and development of therapeutic applications of Sangamo's gene therapy and ZFP technology platforms, the potential of Sangamo's technology to treat hemophilia and lysosomal storage disorders, the expected timing of these clinical trials and the release of data from these trials, the impact of Sangamo's clinical trials on the field of genetic medicine and the benefit of orphan drug status. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to substantial dependence on the clinical success of lead therapeutic programs, the initiation and completion of stages of our clinical trials, whether the clinical trials will validate and support the tolerability and efficacy of ZFNs, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. For a more detailed discussion of these and other risks, please see Sangamo's SEC filings, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo Therapeutics, Inc. assumes no obligation to update the forward-looking information contained in this press release.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sangamo-therapeutics-receives-orphan-drug-designation-from-the-fda-for-sb-913-genome-editing-treatment-for-mps-ii-300415719.html

SOURCE Sangamo Therapeutics, Inc.

http://www.sangamo.com

Go here to read the rest:
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 Genome Editing Treatment for ... - PR Newswire (press release)

share

pin

email

During his address to Congress last night, President Donald Trump introduced Megan Crowley, a 20-year-old woman with a rare disease.

Crowley, who has a neuromuscular disorder known as Pompe disease, credits her survival to her father's small biotechnology company for developing and producing a therapy for the rare genetic mutation.

During the speech, the President suggested that Crowleys story highlighted the need to scale back regulations and to streamline the processes of the Food and Drug Administration. While Crowley's doctor welcomed the spotlight shown on Pompe disease and on rare diseases, in general, others cautioned that rushing experimental treatments through the Food and Drug Administration could have disastrous results.

Related: Speed up drug approvals? The FDA already did

The big problem isnt with the FDAs procedures, but rather a shortage of funds and the small numbers of people in whom scientists can study the ailments, researcher Dr. Puneet Opal told TODAY.

FDA drug approval procedures are intended to prevent patient deaths from experimental treatments, said Opal, a professor of neurology at Northwestern Universitys Feinberg School of Medicine.

"You do need the FDA to be the police dog," said Opal.

Crowleys physician, Dr. Priya Sunil Kishnani, division chief of medical genetics at the Duke University Medical Center, was excited to have rare diseases given such high-profile attention.

We diagnosed Megan at Duke in 1998 when she was just 15 months old. Its been an amazing journey to see how she has not just survived but is thriving despite her limitations, Kishnani, who is also professor of pediatrics and division chief of medical genetics, told TODAY.

Pompe disease occurs in an estimated 1 in 12,000 to 20,000 babies and people with an adult-onset form, according to Duke University experts. Crowley's fathers struggle to find a cure for the disease was profiled in the book The Cure: How a Father Raised $100 Million and Bucked the Medical Establishment in a Quest to Save His Children and also inspired a 2010 movie called Extraordinary Measures.

Megan Crowley listens as President Donald Trump addresses Congress.

Related: Parents race to save girl with rare, deadly disease

For those not familiar with Pompe, here are five things to know:

That means that a child must inherit two copies one from each parent to be affected by it. Children born with just one copy of the mutated gene are healthy and generally are completely unaware they have it.

When someone has both copies of the mutated gene, the body lacks enough of an enzyme that breaks down the starch glycogen into glucose, a form of sugar that fuels the muscles. The result is a damaging overabundance of glycogen.

Because the heart is also a muscle, damage to it is what generally kills patients even before there is respiratory distress, Opal said.

In babies, the earliest symptoms are not meeting motor milestones, Kishnani said. Babies might not hold their heads up or start rolling over at the expected age. They may not have the same strength as other babies of similar age.

"When you pick them up you feel like theyre almost slipping through your fingers," said Kishnani.

Respiratory symptoms or pneumonia might reveal a massively enlarged heart.

The severity of the symptoms and when they appear depend on the exact type of mutation. There are children who show up with worse symptoms than Crowley and others who show up with milder ones, Kishnani said.

The treatment isnt a cure for the disease, but it is lifesaving. Crowley is confined to a wheelchair and must use a ventilator to breathe.

These individuals do have a life," said Kishnani, talking about Megan's spunk and passion.

"She has life goals. People should not just look past her ... and think there are not going to be any cognitive abilities.

Read more here:
What is Pompe disease? 5 things to know about the rare gene mutation - Today.com

Could This Treatment Cure Cancer?

Despite the many advances in medicine over the last century, a cure for one of the most prevalent and devastating diseases in the world todaycontinues to evade us. But thanks to new research, that could soon change.

Kite Pharma, a US pharmaceutical company, just released the groundbreaking results of their six-month gene therapy trial: terminal cancer patients incomplete remission after just a single round.

The treatment filters a patients blood to remove T-cells, immune system cells that can be genetically engineered in a lab to identify cancer cells. Cancer cells thrive because of their ability to evade the immune system.This new therapy boosts immune cells so that they are able to eliminate cancer cells more effectively.

Patients who participated in the trial had one of three types of non-Hodgkin lymphoma. The advanced stageof their conditions meant all of them were given only a few months to live. However, following the first round of gene therapy, which took place nine months after the trial began, half the patients are not only still alive, but a third of themappear to be cured.

Among them is a 43- year-old named Dimas Padilla from Orlando, Florida whose cancer had stopped responding to chemotherapy. He completed the first round of the trials treatment last August, and his cancer is now in remission.

These results are promising and suggest that one day CAR-T cells could become a treatment option for some patients with certain types of lymphoma, said head cancer information nurse, Martin Ledwick from the Cancer Research UK, in an interview with The Telegraph.

While the results are promising and could prove to be life- changing for patients with terminal cancer, the treatment is not without risks.

Because the therapy essentially puts the human immune system to go into overdrive by radically altering human cells, complications are certainly possible some of which could be fatal. In fact, during the trial, two people diedas a resultof the therapy not because of the cancer. Some patientsimmune systems overreacted in its effort to kill the cancer cells, while others developed blood-count related issues such as anemia. Reports of patients suffering from neurological problems were also cited, but these side effectsapparently only lasted a few days.

More studies are needed tounderstand the therapys side effects, potential complications, and long-term benefits.

The trials full results wont be presented until April, and the pharmaceutical company still has to get approval from the European regulatory boards which means it will be a while yet before the therapy becomes available. Given the possible risks, it might give them enough time to study the therapy further and refine the process hopefully eliminating any adverse effects.

Although, as the Cancer Institutes Dr. Steven Rosenberg points out: Its a safe treatment, certainly a lot safer than having progressive lymphoma.

Excerpt from:
A New Cancer Treatment Has Given Terminal Patients a Second Chance at Life - Futurism